P1/2, N=164, Recruiting, Betta Pharmaceuticals Co., Ltd.

The progression-free survival (PFS) exceeded 32 months, with no significant treatment-related adverse events observed. This study investigates the feasibility of combining targeted therapy with local radiotherapy, guided by genetic testing, to offer novel treatment strategies for patients with advanced primary pulmonary EIMS..

In the present study, we investigated whether combining reduced-dose 177Lu-CD25 Ab radioimmunotherapy (RIT) with molecularly targeted inhibitors of ALK (crizotinib) or mTOR (everolimus) could enhance antitumor efficacy while minimizing systemic toxicity. These findings demonstrate that targeted inhibition of ALK or mTOR synergizes with CD25-directed 177Lu RIT to enhance therapeutic efficacy without increasing toxicity. This combinatorial approach enables radiation-dose reduction while preserving antitumor potency, supporting further preclinical and translational development of 177Lu-CD25-based combination RIT for ALCL and other CD25-expressing malignancies.

The last follow-up in August 2025 showed the patient remained in good survival status. This case highlights a novel strategy of neoadjuvant targeted downstaging followed by surgical resection for small-lesion, highly invasive NSCLC, as well as the potential value of integrating postoperative Chinese-Western medicine management for long-term survival and treatment tolerance.

Treatment of cancer patients with selective ALK inhibitors, such as Ceritinib, causes dysgeusia. Mice receiving Ceritinib had a dramatic reduction in taste bud volume and innervation, and a significant portion of PHOX2B+ neurons died, demonstrating that ALK is critical for development and maintenance of oral sensory neurons.

P2, N=118, Active, not recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Trial completion date: Jan 2026 --> Apr 2026 | Trial primary completion date: Jan 2026 --> Apr 2026

P3, N=220, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting

P1, N=27, Completed, H. Lee Moffitt Cancer Center and Research Institute | Active, not recruiting --> Completed

Pharmacologic and genetic inhibition of N-cad synergized with dasatinib and brigatinib, two kinase inhibitors with efficacy in NF2-SWN, to suppress schwannoma proliferation and tumor growth. These findings establish N-cad as a central regulator of schwannoma migration and a novel therapeutic target.

Notably, the Gly2032Arg mutation in the ROS1 protein has been linked to resistance against the kinase inhibitor crizotinib...Density functional theory (DFT) at the B3LYP/6-31G* level was performed to elucidate molecular features of the identified compounds. Overall, this study sheds light on a new series of compounds effective against mutated targets, thereby offering a new horizon in this area.

After two years of therapy, the child has sustained partial tumor regression on MRI and no new neurological symptoms. We conclude that comprehensive multi-omics analyses are required for correct molecular diagnosis in childhood CNS tumors and can radically impact patient outcome by identifying molecular targets for precision treatment.